GHENT, BELGIUM--(Marketwire - November 19, 2008) - REGULATED INFORMATION Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today provides its non-audited business update, in compliance with the EU transparency directive, summarising material events and Ablynx’s financial position for the third quarter of 2008 and approved by the Board of Directors on 19 November 2008.
